Wegovy Self-Injection Technique: A Step-by-Step Clinical Guide

How Wegovy Works Before You Pick Up the Pen

Semaglutide 2.4 mg is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the incretin hormone GLP-1, which your gut releases after eating. The drug binds to GLP-1 receptors in the hypothalamus to reduce appetite, slows gastric emptying to increase satiety, and improves insulin sensitivity in peripheral tissues [1]. Its 94% amino acid homology to native human GLP-1, combined with albumin binding and enzymatic resistance, gives it a half-life of approximately 7 days, which is what makes once-weekly dosing possible [2].

In the STEP-1 trial (N=1,961), participants receiving semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks compared with 2.4% in the placebo group (estimated treatment difference: -12.4 percentage points; 95% CI, -13.4 to -11.5; P<0.001) [1]. A total of 86.4% of semaglutide-treated participants achieved at least 5% weight loss, and 69.1% achieved at least 10%. These results depend on consistent weekly dosing, which in turn depends on correct injection technique.

The SELECT cardiovascular outcomes trial (N=17,604) later demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg versus placebo (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001) in adults with overweight or obesity and established cardiovascular disease [3]. That finding led to an expanded FDA indication in March 2024 for cardiovascular risk reduction [4].

Understanding the Wegovy FlexTouch Pen

Each Wegovy pen is prefilled with a single dose and is discarded after one use. There is no need to attach a separate needle. The pen contains a pre-attached, hidden 29-gauge, 6 mm thin-wall needle that remains concealed until the pen is pressed against the skin and the injection button is clicked. This design was specifically developed to reduce needle anxiety, a barrier identified in adherence studies of injectable GLP-1 receptor agonists [5].

The pen has three main components: a pen cap (gray), a dose window, and a dose button. When the dose window shows the flow indicator, the dose is being delivered. After completion, the window turns yellow, confirming the full dose has been injected. This visual confirmation system eliminates guesswork.

Five pen strengths correspond to the dose escalation schedule: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Each pen strength has a distinct label color to prevent dosing errors [4].

Preparing for Your Injection

Remove the pen from the refrigerator 30 minutes before injection to allow it to reach room temperature. Cold injections are more likely to cause discomfort and local site reactions. Inspect the solution through the pen window: it should be clear, colorless to slightly yellow, and free of particles. Do not use the pen if the solution appears cloudy, discolored, or contains visible particulate matter [4].

Wash your hands with soap and water. Clean the injection site with an alcohol swab and allow it to air dry completely. Injecting through wet alcohol can cause stinging. Gather a sharps disposal container before you begin. These steps take roughly 60 seconds but prevent the two most common user errors flagged in the Wegovy prescribing information: injecting a cold pen and failing to have a sharps container ready [4].

Do not shake the pen. Semaglutide is a biologic peptide, and vigorous agitation can cause protein aggregation that reduces efficacy.

Choosing and Rotating Your Injection Site

The three FDA-approved injection sites are the abdomen (at least 2 inches from the navel), the front of the thigh (mid-thigh area), and the back of the upper arm (the upper arm site typically requires assistance from another person) [4]. All three sites provide reliable subcutaneous absorption for semaglutide. A pharmacokinetic study of subcutaneous semaglutide showed comparable bioavailability across abdominal, thigh, and upper arm sites (relative bioavailability ratios within 0.90 to 1.11) [6].

Rotate injection sites each week. If you prefer the abdomen, alternate between the left and right side. If you favor the thigh, switch legs. Rotation reduces the risk of lipohypertrophy (localized fat thickening) or lipoatrophy (fat loss), both of which can impair drug absorption over time. The American Diabetes Association's injection technique guidelines recommend a minimum spacing of 1 inch (2.5 cm) between consecutive injection points within the same anatomic region [7].

Avoid injecting into skin that is bruised, tender, red, hard, scarred, or has stretch marks. These areas have altered subcutaneous tissue architecture that can affect drug delivery.

Step-by-Step Injection Instructions

Step 1: Remove the pen cap. Pull off the gray pen cap. You will see the hidden needle cover, which sits flush with the pen tip. Do not touch the needle cover.

Step 2: Position the pen. Hold the pen with the dose window visible. Place the pen tip flat against the cleaned injection site at a 90-degree angle to the skin. Do not pinch the skin unless you are very lean (BMI <27 with minimal subcutaneous fat at the chosen site), in which case a gentle skin fold helps ensure subcutaneous delivery rather than intramuscular injection [7].

Step 3: Inject the dose. Press and hold the dose button. You will hear a first click, indicating the injection has started. Keep the pen pressed firmly against the skin. The flow indicator will appear in the dose window.

Step 4: Wait for the yellow indicator. Hold the pen against the skin until the dose window turns completely yellow. This typically takes 5 to 10 seconds. The yellow window confirms the full dose has been delivered. You will hear a second click. Lifting the pen before the window turns yellow results in a partial dose that cannot be corrected with the same pen.

Step 5: Remove and dispose. Lift the pen straight away from the skin. A small drop of blood at the injection site is normal. Do not rub the area. Replace the pen cap and place the entire used pen into a FDA-cleared sharps disposal container. Never reuse a pen or attempt to recap the hidden needle separately [4].

The 16-Week Dose Escalation Schedule

Wegovy uses a mandatory dose escalation to reduce gastrointestinal side effects. The schedule, per the prescribing information, is as follows [4]:

• Weeks 1 to 4: 0.25 mg once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9 to 12: 1 mg once weekly
• Weeks 13 to 16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance dose)

Each escalation step uses a different pen strength. In the STEP-1 trial, 74.2% of participants successfully escalated to and tolerated the full 2.4 mg maintenance dose [1]. The most common reasons for not reaching maintenance were gastrointestinal adverse events, primarily nausea (44.2% of semaglutide-treated participants), diarrhea (31.5%), and vomiting (24.8%) [1].

If you cannot tolerate a dose increase, the Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends extending the current dose step for an additional 4 weeks before reattempting escalation, rather than abandoning the drug [8]. Dr. Caroline Apovian, co-author of the Endocrine Society guideline, has stated: "Dose escalation flexibility is key to retention on GLP-1 therapy. A patient who tolerates 1.7 mg is still getting meaningful weight loss compared to stopping entirely."

Storage, Missed Doses, and Travel

Unused Wegovy pens must be stored in the refrigerator at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). Once removed from refrigeration, a pen can be kept at room temperature below 30 degrees Celsius (86 degrees Fahrenheit) for up to 28 days. After 28 days at room temperature, the pen must be discarded even if unused [4]. Do not freeze Wegovy. If a pen has been frozen, discard it.

For a missed dose, the FDA-approved labeling offers a clear rule: if fewer than 5 days have passed since the missed dose, inject it as soon as possible and then resume the regular weekly schedule. If 5 or more days have passed, skip the missed dose and administer the next dose on the regularly scheduled day [4]. Frequent missed doses may require restarting the escalation schedule, particularly if the gap exceeds 2 consecutive weeks, to avoid rebound gastrointestinal intolerance.

When traveling, use an insulated medication travel pouch with a cold pack to maintain temperature. TSA and international aviation authorities allow injectable medications through security with the prescription label. Keep pens in carry-on luggage. Checked baggage holds can reach subzero temperatures that destroy the drug.

Avoiding Common Injection Errors

A 2020 analysis of injection technique errors across GLP-1 receptor agonists found that 31% of patients using prefilled pens made at least one technique error within the first 3 months of therapy [9]. The most frequently reported errors with pen injectors include:

Lifting the pen too early. Removing the pen before the dose window turns yellow delivers a partial dose. Because each Wegovy pen is single-use, the remaining drug cannot be recovered. If this occurs, do not attempt a second injection. Contact your prescriber to determine whether to wait until the next scheduled dose or use a replacement pen.

Injecting into the same spot repeatedly. Repeated injection into one location causes lipohypertrophy, which the International Diabetes Federation estimates affects up to 50% of insulin-injecting patients and likely occurs at similar rates with weekly GLP-1 pens [7]. Lipohypertrophic tissue absorbs drug unpredictably, leading to variable blood levels and inconsistent efficacy.

Failure to let the pen reach room temperature. Cold medication increases injection pain and can cause localized vasospasm that slows absorption. Thirty minutes at room temperature is the minimum recommended equilibration time [4].

Not pressing firmly enough. The FlexTouch pen requires firm, flat contact with the skin to retract the needle safety shield and initiate injection. Light or angled contact will prevent the mechanism from engaging.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington and a long-standing authority on injection technique, has noted: "The simplicity of modern auto-injector pens can create a false sense that technique does not matter. Proper pen contact, adequate hold time, and site rotation remain just as important as they were with vial-and-syringe regimens."

When to Seek Medical Attention After Injection

Most injection-site reactions are mild: transient redness, mild swelling, or slight itching that resolves within 24 hours. In STEP-1, injection-site reactions occurred in 3.2% of semaglutide-treated participants versus 2.0% in the placebo group [1].

Contact your prescribing clinician if you experience any of the following after injection: a hard lump larger than 2 cm that persists beyond 48 hours, signs of local infection (expanding redness, warmth, pus, or fever), severe or worsening abdominal pain (a potential signal of pancreatitis, reported in 0.2% of participants in STEP trials), or symptoms of a systemic allergic reaction such as facial swelling, difficulty breathing, or widespread rash [4].

Wegovy carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies. While no causal relationship has been established in humans, patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Wegovy [4]. Report any new neck mass, dysphagia, or persistent hoarseness to your physician promptly.

The maintenance dose of semaglutide 2.4 mg, when injected correctly once weekly, reduced HbA1c by 1.6 percentage points and waist circumference by 13.54 cm versus placebo at 68 weeks in the STEP-1 population [1].